The partnership aims to optimise Regor’s platform to identify targets and treatments that meet the individuals’ requirements and preferences. Credit: aslysun/Shutterstock. Sermonix Pharmaceuticals and Regor Therapeutics have announced a strategic partnership to discover and develop therapeutics in the breast oncology […]
Sermonix and Regor to enhance breast cancer treatment options Read More »
GSK’s mepolizumab programme in chronic obstructive pulmonary disease includes three studies. Credit: HJBC/Shutterstock. The European Medicines Agency (EMA) has agreed to review GSK’s application of expanding Nucala’s (mepolizumab) use as add-on maintenance for individuals with chronic obstructive pulmonary disease (COPD)
EMA to review GSK’s Nucala for COPD treatment expansion Read More »
The Arthur JE Child Comprehensive Cancer Centre. Credit: Alberta Health Services/Siemens Healthineers AG ©2025. The government of Alberta, Canada, has announced a collaboration with Siemens Healthineers and the Alberta Cancer Foundation, investing C$800m ($560m) over eight years to enhance cancer
Alberta partners with Siemens and Alberta Cancer Foundation Read More »
The company’s mRNA therapies include TAA cancer vaccines, immunomodulatory cancer vaccines, in vivo CAR-T therapies and personalised cancer vaccines. Credit: Pormezz/Shutterstock. The US Food and Drug Administration (FDA) has approved an investigational new drug (IND) application for Everest Medicines’ tumour-associated
FDA approves IND application of Everest’s cancer vaccine Read More »
AstraZeneca anticipates that the expansion will increase its workforce in the region to 1,700. Credit: Robert Way/Shutterstock. AstraZeneca has announced a $2.5bn investment in the company’s sixth worldwide strategic research and development (R&D) centre in Beijing, China. The initiative, which
AstraZeneca announces $2.5bn investment in R&D centre in China Read More »
The bridging study’s main objective is to assess the objective response rate of the therapy in subjects with R/R FL with EZH2 mutations. Credit: Chay_Tee/Shutterstock. China’s National Medical Products Administration (NMPA) has granted conditional approval for Hutchmed’s Tazverik (tazemetostat) to
China conditionally approves Hutchmed’s Tazverik for FL Read More »
The software provides a database of clinical images to help healthcare professionals diagnose skin conditions. Credit: Evgeniy Kalinovskiy/Shutterstock. The Menarini Group, along with its subsidiary Stemline Therapeutics, has announced a partnership with VisualDx to enhance the detection of blastic plasmacytoid
Menarini to enhance BPDCN detection with VisualDx’s partnership Read More »
Johnson & Johnson developed the dual-acting monoclonal antibody. Credit: Skorzewiak/Shutterstock. Johnson & Johnson (J&J) has received US Food and Drug Administration (FDA) approval for its interleukin 23 inhibitor, Tremfya (guselkumab), to treat moderately to severely active Crohn’s disease (CD) in
J&J gains FDA approval for Tremfya to treat Crohn’s disease Read More »
The therapy is undergoing Phase I clinical development. Credit: Alex_Traksel/Shutterstock. Servier and Black Diamond Therapeutics have signed a licensing agreement for a targeted therapy, BDTX-4933, to treat solid tumours. Servier will be responsible for the development and the global commercialisation
Servier and Black Diamond sign deal for solid tumours therapies Read More »
Pfizer is set to obtain all net proceeds from the offering. Credit: © 2025 Pfizer Inc. All rights reserved. Pfizer has divested its entire residual shareholding in Haleon, representing 7.3% of the company’s issued share capital, for £2.55bn ($3.3bn), as
Pfizer sells 7.3% stake in Haleon for $3.3bn Read More »
